⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TPST News
Tempest Therapeutics, Inc. Common Stock
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
globenewswire.com
TPST
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
globenewswire.com
TPST
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
globenewswire.com
TPST
Tempest Reports Year End 2025 Financial Results and Provides Business Update
globenewswire.com
TPST
Form 8-K
sec.gov
TPST
Form 8-K
sec.gov
TPST
Tempest Therapeutics Announces Up To $6 Million Private Placement
globenewswire.com
TPST
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
globenewswire.com
TPST
Form 8-K
sec.gov
TPST
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
globenewswire.com
TPST